Older News Items

29th-October-2021

A double-blind randomized controlled trial shows transcranial magnetic stimulation caused remission in 79% of trial participants with severe depression


11th-October-2021

Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer’s disease


4th-October-2021

Personalized closed-loop neuromodulation therapy resulted in a rapid and sustained improvement in depression


22nd-September-2021

Patterns of pre-treatment reward task brain activation predict individual antidepressant response


15th-September-2021

Repurposing anti-cancer drugs to modulate cerebrovascular neoangiogenesis may provide an effective treatment for AD and related vascular diseases of the brain


26th-August-2021

Inflammation in the brain drives the progression from the presence of amyloid plaque and tau tangles to the onset of dementia and Alzheimers disease


18th-August-2021

Key mechanisms behind synapse degeneration in Alzheimer’s brain discovered


30th-July-2021

MIA-690, a novel growth hormone releasing hormone (GHRH) antagonist, exhibits anxiolytic and antidepressant-like effects in mouse model


14th-July-2021

Astrocytic interleukin-3 programs microglia and limits Alzheimer disease


5th-July-2021

Psilocybin ameliorates stress-related behavioral deficit in mice and increases spine density and spine size in frontal cortical pyramidal cells


28th-June-2021

Normal cognition and hippocampal volume are associated with preservation of high soluble A-beta42 levels despite increasing brain amyloidosis


28th-June-2021

Sustained effects of rapidly acting antidepressants require BDNF-dependent MeCP2 phosphorylation


15th-June-2021

Innate immunity stimulation via CpG oligos ameliorates Alzheimers disease pathology in aged squirrel monkeys


9th-June-2021

Calcineurin inhibitor,Tacrolimus, protects against age-associated microstructural changes in the beagle brain


26th-May-2021

Targeted proteasome enhancement reduces post-synaptic Tau